Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (CD3/CD19 Haplo)

29. juni 2022 opdateret af: Prof. Dr. med. Wolfgang Bethge, University Hospital Tuebingen

Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia

Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity conditioning regimen with CD3/CD19 depleted grafts. This study enrolls patients with acute leukemia in complete remission with an indication for allogeneic HCT but without a suitable HLA-identical donor

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

23

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Dresden, Tyskland, D-01307
        • University of Dresden Medical Center
      • Essen, Tyskland, 45122
        • Center for Marrow Transplantation, University of Essen
      • Halle, Tyskland, 06120
        • Medical Center University of Halle
      • Hamburg, Tyskland, 20246
        • Medical Center University of Hamburg
      • Muenster, Tyskland, 48149
        • Medical Center University of Muenster
      • Tuebingen, Tyskland, 72076
        • South West German Cancer Center, University of Tuebingen Medical Center
      • Wiesbaden, Tyskland, 65191
        • Deutsche Klinik für Diagnostik
      • Wuerzburg, Tyskland, D-97070
        • University of Wuerzburg Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Patients with either ALL or AML in CR with an indication for allogeneic HCT according to the following criteria:
  • AML: high risk patients with one or more of the following risk factors:

    • FLT-3 mutation
    • Complex cytogenetics
    • abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p)
    • Late CR > induction I
    • Age >60
    • Patients in 2.CR
    • Secondary AML
    • Relapse after a preceding allogeneic HCT from an HLA-identical donor
  • ALL: high risk patients with one or more of the following risk factors:

    • Pro-B-ALL
    • Initial WBC >30.000/µL
    • CR after day 46 after Induction II
    • Complex cytogenetics, t(9,22), t(4,11)
    • Early or mature T-ALL
    • Initially refractory patients with late CR
    • Rising MRD level
    • Patients in 2. CR
    • Relapse after a preceding allogeneic HCT from an HLA-identical donor
    • No HLA-identical donor (not more than 1 antigen mismatch (9/10-Match) or more than 2 allelic mismatches by high-resolution typing). Critical cases should be discussed with the PI.
    • Age <=65, >=18 years
    • Karnofsky Index >60%

Exclusion Criteria:

  • Patients with >5% blasts in BM at the time of transplantation
  • Less than 3 months after preceding HCT
  • CNS involvement with disease
  • History of neurologic impairment such as: seizures, severe peripheral neuropathy, signs of leukoencephalopathy, CNS infection, multiple intrathecal chemotherapies, CNS irradiation. In case of heavy pretreatment with irradiation or intrathecal chemotherapy pretransplant CNS MRI and neurological consultation are mandatory
  • Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month.
  • Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher 2x upper limit of normal.
  • Chronic active viral hepatitis
  • Ejection fraction <40 % on echocardiography
  • Patients with > grade II hypertension by CTC criteria
  • Creatinine clearance <50 ml/min
  • Respiratory failure necessitating supplemental oxygen or DLCO <30%
  • Allergy against murine antibodies
  • HIV-Infection
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter. (Women of childbearing potential must have a negative serum pregnancy test at study entry)
  • Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
  • Patients with a history of psychiatric illness or condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
  • Patients unwilling or unable to comply with the protocol
  • Unable to give informed consent
  • Enrollment in an other trial interfering with the endpoints of this study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Evaluation of treatment related mortality after haploidentical HCT
Tidsramme: 1 year after HCT
Cumulative Incidence of treatment related mortality
1 year after HCT

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
overall survival
Tidsramme: 1, 2 and 5 years after inclusion
by Kaplan-Meier
1, 2 and 5 years after inclusion
Evaluate Engraftment
Tidsramme: One year after HCT
One year after HCT
Evaluate Toxicity
Tidsramme: One year after HCT
One year after HCT
Evaluate Disease Free Survival
Tidsramme: 1, 2 and 5 years after inclusion
1, 2 and 5 years after inclusion

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Wolfgang A. Bethge, MD, Medical Center University Hospital Tuebingen

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. juni 2009

Primær færdiggørelse (Faktiske)

30. december 2015

Studieafslutning (Faktiske)

30. december 2015

Datoer for studieregistrering

Først indsendt

17. august 2009

Først indsendt, der opfyldte QC-kriterier

17. august 2009

Først opslået (Skøn)

18. august 2009

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. juli 2022

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. juni 2022

Sidst verificeret

1. juni 2022

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner